Prosecution Insights
Last updated: April 19, 2026
Application No. 17/409,665

Bioenergy (Biophoton) Generator and Its Use

Final Rejection §103
Filed
Aug 23, 2021
Examiner
MONSHIPOURI, MARYAM
Art Unit
1651
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Tesla Biohealing Inc.
OA Round
10 (Final)
79%
Grant Probability
Favorable
11-12
OA Rounds
2y 3m
To Grant
99%
With Interview

Examiner Intelligence

Grants 79% — above average
79%
Career Allow Rate
756 granted / 956 resolved
+19.1% vs TC avg
Strong +37% interview lift
Without
With
+37.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 3m
Avg Prosecution
28 currently pending
Career history
984
Total Applications
across all art units

Statute-Specific Performance

§101
2.9%
-37.1% vs TC avg
§103
23.9%
-16.1% vs TC avg
§102
17.2%
-22.8% vs TC avg
§112
36.3%
-3.7% vs TC avg
Black line = Tech Center average estimate • Based on career data from 956 resolved cases

Office Action

§103
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2/26/26 has been entered. Claims 1-2, 4, 7, 28 are still at issue and under consideration. Claims 3, 5-6, 8-27 have been canceled. Applicants' arguments filed on 2/26/26, have been fully considered and are deemed to be persuasive to overcome some of the rejections previously applied. Rejections and/or objections not reiterated from previous office actions are hereby withdrawn. Claim Rejections - 35 USC § 103 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1-2, 4, 7, 28 remain rejected under 35 U.S.C. 103 as being unpatentable over Bartel et al., “Bartel” (US2019/0125028, 5/2019), optionally in view of hygienic article storage techniques. Bartel in its abstract teaches that its invention is directed to articles that include one or more coated fiber(s) (i.e., fiber(s) with a cured coating disposed thereon), where the coating includes a matrix of crosslinked polymers and optionally a colorant (e.g., pigment particles or dye or both). Bartel also points out that its invention is further directed to articles including the coated fibers, methods of forming the coated fibers and articles, and methods of making articles including the coated fibers. In [0009], according to Bartel, its disclosure is also directed to a composite article, where the composite article comprises a solid resin material (e.g., a solid thermoplastic material or a solid thermoset material such as an epoxy resin material) consolidating the one or more coated fiber(s) as disclosed herein. When present, the optional colorants (e.g., pigments or dye or both) impart color or decorative effects to the fiber(s) and the articles, which can be realized by coating one or more fiber(s) with the coating composition and curing the coating composition prior to consolidating the one or more fiber(s) with the solid resin material. In [0026], Bartel teaches that one or more coated fiber(s), can be incorporated into a tow, a yarn or a cable, and can be used in fiber form or yarn form to form a textile. For example, a textile comprising the one or more coated fiber(s) can be used to form footwear or components thereof, apparel (e.g., shirts, jerseys, pants, shorts, gloves, glasses, socks, hats, caps, jackets, undergarments) or components thereof, containers (e.g., backpacks, bags). In addition, the one or more coated fiber(s) can be used to produce articles or other items that are disposed on the article, where the article can be eye wear. In [0181], Bartel elaborates on fillers which may be used to increase strength and other physical properties of its crosslinked polymers such as polyurethane, polypropylene, methacrylate, copolymers (see [10134]) etc.), wherein said crosslinked polymers can be considered to be the unactivated ingredient(s) of this invention. Bartel further mentions that the fillers can be clay, talc, mica, glauconite (wherein said components are part of sand by inherency), as well as copper, iron and tourmaline. Given the teachings of Bartel, one of ordinary skill before the effective filing of this invention, can envisage for example utilizing the method of Bartel to prepare methacrylate made eye wear articles such as rigid contact lenses, with fillers such as one or more of copper, tourmaline, clay, talc, mica, glauconite. Said reference however, does not explicitly mention about storing said rigid contact lenses in a contact Lense solution in a sealed plastic container. Current hygienic article storage techniques teach that it is best to store contact lenses in a sterile contact Lense solution (made of water, solvents and slats etc.) that is sealed in a plastic container because this inexpensive packaging technique avoids drying up and contamination of said lenses and wherein said packaging eases portability of said contact lenses. Before the effective filing of this application, it would have been obvious to one of ordinary skill in the art to start with the rigid contact lens preparation method of Bartel and after production, store said lenses in a contact lens solution sealed in a plastic container, according to current hygienic article storage techniques. Such sealed plastic contact Lense storage container is inherently a bioenergy generator, which produces biophotons as measured by a biophoton detector, rendering this invention obvious. Finally, one of ordinary skill in the art has a reasonable expectation of success in preparing rigid contact lenses of Bartel using the instructions of Bartel and storing said contact lenses in a contact lens solution in a plastic container that is sealed, according to current hygienic article storage techniques because the prior art was fully established as to how to prepare rigid contact lenses and how to store said products to maintain hygiene and ensure convenience, before the effective filing of this application. Applicant is reminded that preparing eye wear articles such as rigid contact lenses, using various relative proportions of its construction components (see claims 2, 4 and 7), was well within the skill of one of ordinary skill in the art, before the effective filing of this application, and cannot be considered to be a contribution over the prior art. No claim is allowed. Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP § 706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to MARYAM MONSHIPOURI whose telephone number is (571)272-0932. The examiner can normally be reached full-flex. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Melenie L Gordon can be reached at 571-272-8037. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /MARYAM MONSHIPOURI/Primary Examiner, Art Unit 1651
Read full office action

Prosecution Timeline

Aug 23, 2021
Application Filed
Sep 22, 2022
Non-Final Rejection — §103
Dec 27, 2022
Response Filed
Jan 17, 2023
Examiner Interview (Telephonic)
Apr 11, 2023
Final Rejection — §103
Aug 10, 2023
Request for Continued Examination
Aug 14, 2023
Response after Non-Final Action
Aug 17, 2023
Final Rejection — §103
Oct 04, 2023
Request for Continued Examination
Oct 11, 2023
Response after Non-Final Action
Oct 23, 2023
Examiner Interview (Telephonic)
Oct 27, 2023
Final Rejection — §103
Apr 26, 2024
Request for Continued Examination
Apr 29, 2024
Response after Non-Final Action
May 11, 2024
Final Rejection — §103
Nov 12, 2024
Applicant Interview (Telephonic)
Nov 12, 2024
Examiner Interview Summary
Nov 15, 2024
Request for Continued Examination
Nov 18, 2024
Response after Non-Final Action
Nov 19, 2024
Examiner Interview (Telephonic)
Nov 20, 2024
Final Rejection — §103
Apr 25, 2025
Response after Non-Final Action
May 22, 2025
Request for Continued Examination
May 27, 2025
Response after Non-Final Action
Jul 07, 2025
Final Rejection — §103
Oct 07, 2025
Request for Continued Examination
Oct 08, 2025
Response after Non-Final Action
Oct 24, 2025
Final Rejection — §103
Dec 12, 2025
Response after Non-Final Action
Jan 12, 2026
Request for Continued Examination
Jan 14, 2026
Response after Non-Final Action
Jan 17, 2026
Final Rejection — §103
Feb 26, 2026
Request for Continued Examination
Mar 04, 2026
Response after Non-Final Action
Mar 18, 2026
Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12584150
ENDOGENOUS LIPASE FOR METAL REDUCTION IN DISTILLERS CORN OIL
2y 5m to grant Granted Mar 24, 2026
Patent 12577572
COMPOSITIONS, SYSTEMS, AND METHODS FOR HIGH LEVEL EXPRESSION OF RECOMBINANT PROTEIN
2y 5m to grant Granted Mar 17, 2026
Patent 12577571
Mutant Dnase1L3 with Improved Serum Half-Life
2y 5m to grant Granted Mar 17, 2026
Patent 12565669
OPTIMIZED PROCESS FOR PRODUCING SECOND-GENERATION SUGARS AND FERMENTATION PRODUCTS
2y 5m to grant Granted Mar 03, 2026
Patent 12559782
FUNGAL STRAINS COMPRISING ENHANCED PROTEIN PRODUCTIVITY PHENOTYPES AND METHODS THEREOF
2y 5m to grant Granted Feb 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

11-12
Expected OA Rounds
79%
Grant Probability
99%
With Interview (+37.3%)
2y 3m
Median Time to Grant
High
PTA Risk
Based on 956 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month